Zadaxin thymosin alpha 1 data

SCLN (San Mateo, Calif.) reported to shareholders an interim analysis of a Phase III non-blinded trial in Taiwan, saying that efficacy was not yet assessable, but that no adverse effects have appeared.

Preliminary findings on DNA markers for the virus show that all five patients who have been in the 12-month treatment group for 10 months have become DNA-negative. The company noted that the patients in the six-month treatment group do not yet differ significantly from controls. ...